COR
Cencora Inc
$
292.165
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
292.720
Open
286.250
VWAP
289.07
Vol
267.07K
Mkt Cap
55.28B
Low
285.350
Amount
77.20M
EV/EBITDA(TTM)
13.52
Total Shares
196.93M
EV
61.52B
EV/OCF(TTM)
35.31
P/S(TTM)
0.18
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
79.95B
+5.96%
4.861
+9.97%
86.47B
+6.11%
4.086
+9.54%
83.63B
+5.8%
3.813
+14.15%
Estimates Revision
The market is revising Downward the revenue expectations for Cencora, Inc. (COR) for FY2025, with the revenue forecasts being adjusted by -0.07% over the past three months. During the same period, the stock price has changed by 4.95%.
Revenue Estimates for FY2025
Revise Downward
-0.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.19%
In Past 3 Month
Stock Price
Go Up
+4.95%
In Past 3 Month
10 Analyst Rating
14.80% Upside
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 335.40 USD with a low forecast of 300.00 USD and a high forecast of 355.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
14.80% Upside
Current: 292.165
Low
300.00
Averages
335.40
High
355.00
14.80% Upside
Current: 292.165
Low
300.00
Averages
335.40
High
355.00
Morgan Stanley
Erin Wright
Equal Weight
maintain
$313 -> $330
2025-07-16
Reason
Morgan Stanley
Erin Wright
Price Target
$313 -> $330
2025-07-16
maintain
Equal Weight
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on Cencora to $330 from $313 and keeps an Equal Weight rating on the shares.
Jefferies
Hold
maintain
$275 -> $300
2025-06-30
Reason
Jefferies
Price Target
$275 -> $300
2025-06-30
maintain
Hold
Reason
Jefferies raised the firm's price target on Cencora to $300 from $275 and keeps a Hold rating on the shares. Progress with the pending reconciliation bill and changes Congress has to make to get it over the line in the next few weeks will continue to drive daily trading for most healthcare provider names in the near-term, the analyst tells investors in a research note. The firm views any improvement vs. the Senate Finance Committee version of Medicaid cuts positively for its coverage universe.
Wells Fargo
Equal Weight -> Overweight
upgrade
$274 -> $337
2025-06-03
Reason
Wells Fargo
Price Target
$274 -> $337
2025-06-03
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Cencora to Overweight from Equal Weight with a price target of $337, up from $274.
Wells Fargo
Equal Weight -> Overweight
upgrade
$274 -> $337
2025-06-03
Reason
Wells Fargo
Price Target
$274 -> $337
2025-06-03
upgrade
Equal Weight -> Overweight
Reason
As previously reported, Wells Fargo upgraded Cencora to Overweight from Equal Weight with a price target of $337, up from $274. The firm says that valuation is justified by robust industry backdrop/high estimate achievability and less relative exposure to macro/policy risks. Wells' estimates are generally in-line with consensus but assume much slower U.S. Healthcare growth and takes a fulsome approach to estimating potential impact from M&A driven customer loss, which likely leaves an upside bias to estimates.
Citi
Buy
maintain
$330 -> $355
2025-05-08
Reason
Citi
Price Target
$330 -> $355
2025-05-08
maintain
Buy
Reason
Citi raised the firm's price target on Cencora to $355 from $330 and keeps a Buy rating on the shares. The firm continues to be impressed with Cencora's U.S. results, saying they "firmly establish" the company as a "safe haven" trade amid outsized market volatility. The company posted a "beat-and-raise" quarter largely due to broad-based U.S. strength across its "well-diversified" specialty book of business, the analyst tells investors in a research note.
Baird
NULL -> Outperform
maintain
$314 -> $350
2025-05-08
Reason
Baird
Price Target
$314 -> $350
2025-05-08
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Cencora to $350 from $314 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Cencora Inc (COR.N) is 16.72, compared to its 5-year average forward P/E of 14.00. For a more detailed relative valuation and DCF analysis to assess Cencora Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Overvalued
5Y Average PE
14.00
Current PE
16.72
Overvalued PE
16.10
Undervalued PE
11.90
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Overvalued
5Y Average EV/EBITDA
10.19
Current EV/EBITDA
12.39
Overvalued EV/EBITDA
11.84
Undervalued EV/EBITDA
8.54
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
0.13
Current PS
0.16
Overvalued PS
0.15
Undervalued PS
0.11
Financials
Annual
Quarterly
FY2025Q3
YoY :
+8.65%
80.66B
Total Revenue
FY2025Q3
YoY :
+39.39%
985.52M
Operating Profit
FY2025Q3
YoY :
+41.46%
689.75M
Net Income after Tax
FY2025Q3
YoY :
+45.45%
3.52
EPS - Diluted
FY2025Q3
YoY :
-103.13%
-73.97M
Free Cash Flow
FY2025Q3
YoY :
+17.02%
3.30
Gross Profit Margin - %
FY2025Q3
YoY :
-73.33%
0.36
FCF Margin - %
FY2025Q3
YoY :
+30.30%
0.86
Net Margin - %
FY2025Q3
YoY :
-24.28%
26.73
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
12.7M
USD
5
3-6
Months
19.7M
USD
9
6-9
Months
316.6M
USD
4
0-12
Months
27.7M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2472.49% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
122.8K
Volume
2
6-9
Months
138.3K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.1M
Volume
Months
6-9
6
42.2K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
175.0K
USD
1
3-6
Months
215.0K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
115.5K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
12.7M
USD
5
3-6
Months
19.7M
USD
9
6-9
Months
316.6M
USD
4
0-12
Months
27.7M
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
COR News & Events
Events Timeline
2025-08-06 (ET)
2025-08-06
06:33:33
Cencora raises FY25 adjusted EPS view to $15.85-$16.00 from $15.70-$15.95
2025-08-06
06:31:58
Cencora reports Q2 adjusted EPS $4.00, consensus $3.84
2025-05-13 (ET)
2025-05-13
06:22:08
Trump's drug-price crackdown may lead to minor concessions, WSJ reports
Sign Up For More Events
Sign Up For More Events
News
4.5
08-06BenzingaWall Street Recovers, Apple Rallies 6% On $100-Billion Gov Manufacturing Investment: What's Moving Markets Wednesday?
7.0
08-06BenzingaCencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook
7.0
08-06Yahoo FinanceCencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook
Sign Up For More News
People Also Watch
VLO
Valero Energy Corp
131.465
USD
-1.37%
AXON
Axon Enterprise Inc
838.120
USD
-0.52%
HES
Hess Corp
160.320
USD
+0.95%
PCG
PG&E Corp
15.195
USD
+1.30%
NDAQ
Nasdaq Inc
97.450
USD
+0.62%
LULU
Lululemon Athletica Inc
187.290
USD
-1.13%
BKR
Baker Hughes Co
42.470
USD
-1.89%
D
Dominion Energy Inc
61.690
USD
-0.19%
FICO
Fair Isaac Corp
1311.820
USD
-0.69%
WCN
Waste Connections Inc
189.260
USD
+0.73%
FAQ
What is Cencora Inc (COR) stock price today?
The current price of COR is 292.165 USD — it has increased 2.47 % in the last trading day.
What is Cencora Inc (COR)'s business?
What is the price predicton of COR Stock?
What is Cencora Inc (COR)'s revenue for the last quarter?
What is Cencora Inc (COR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cencora Inc (COR)'s fundamentals?
How many employees does Cencora Inc (COR). have?